Cyrus Harmon - Dec 29, 2023 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
Director
Signature
/s/ Shane Kovacs, Attorney-in-Fact
Stock symbol
OLMA
Transactions as of
Dec 29, 2023
Transactions value $
-$334,500
Form type
4
Date filed
1/2/2024, 05:30 PM
Previous filing
Dec 1, 2023
Next filing
Feb 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Sale -$299K -22.5K -2.43% $13.30 904K Dec 29, 2023 Direct F1, F2
transaction OLMA Common Stock Sale -$35.3K -2.5K -0.28% $14.10 901K Dec 29, 2023 Direct F1, F3
holding OLMA Common Stock 122K Dec 29, 2023 See Footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.
F2 The weighted average sale price for the transaction reported was $13.30, and the range of prices was between $13.15 and $13.87. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 The weighted average sale price for the transaction reported was $14.10, and the range of prices was between $14.08 and $14.27. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F4 The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.